Published • loading... • Updated
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
MapLight Therapeutics is holding to hope that there's a path forward for its autism drug despite the program flunking a mid-stage study. The biotech’s treatment, known as ML-004, didn't meet the Phase 2 trial’s primary ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
